Inhibiting the main protease 3CLpro is the most common strategy in the search for antiviral drugs to fight the infection from SARS-CoV-2. We report that the natural compound eugenol is able to hamper in vitro the enzymatic activity of 3CLpro, the SARS-CoV-2 main protease, with an inhibition constant in the sub-micromolar range (K = 0.81 µM). Two phenylpropene analogs were also tested: the same effect was observed for estragole with a lower potency (K = 4.1 µM), whereas anethole was less active. The binding efficiency index of these compounds is remarkably favorable due also to their small molecular mass (MW < 165 Da). We envision that nanomolar inhibition of 3CLpro is widely accessible within the chemical space of simple natural compounds.

Sub-micromolar inhibition of SARS-CoV-2 3CLpro by natural compounds

Bruno Rizzuti
Primo
;
2021

Abstract

Inhibiting the main protease 3CLpro is the most common strategy in the search for antiviral drugs to fight the infection from SARS-CoV-2. We report that the natural compound eugenol is able to hamper in vitro the enzymatic activity of 3CLpro, the SARS-CoV-2 main protease, with an inhibition constant in the sub-micromolar range (K = 0.81 µM). Two phenylpropene analogs were also tested: the same effect was observed for estragole with a lower potency (K = 4.1 µM), whereas anethole was less active. The binding efficiency index of these compounds is remarkably favorable due also to their small molecular mass (MW < 165 Da). We envision that nanomolar inhibition of 3CLpro is widely accessible within the chemical space of simple natural compounds.
2021
Istituto di Nanotecnologia - NANOTEC - Sede Secondaria Rende (CS)
Inglese
14
892
10
https://doi.org/10.3390/ph14090892
https://www.mdpi.com/1424-8247/14/9/892
Antivirals
Drug selection
Enzyme inhibitors
Eugenol
Main protease
Molecular modeling
SARS-CoV-2
Spectroscopy
9
info:eu-repo/semantics/article
262
Rizzuti, Bruno; Ceballos-Laita, Laura; Ortega-Alarcon, David; Jimenez-Alesanco, Ana; Vega, Sonia; Grande, Fedora; Conforti, Filomena; Abian, Olga; Vel...espandi
01 Contributo su Rivista::01.01 Articolo in rivista
open
File in questo prodotto:
File Dimensione Formato  
Rizzuti et al., Pharmaceuticals 2021;14,892-1-10.pdf

accesso aperto

Descrizione: Rizzuti et al., Pharmaceuticals 2021;14,892-1-10
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.92 MB
Formato Adobe PDF
1.92 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/433973
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 20
social impact